Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Schott Pharma AG KGaACHIX:1SXPD 71 EV-to-FCF is 53.69 as of Jul. 15, 2026, which is 30% below its 10-year median of 76.68. GuruFocus rates CHIX:1SXPD with a GF Score™ of 71/100 and a GF Value™ of €20.10. The stock has 2 warning signs investors should review. Among 414 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks worse than 78.74% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Schott Pharma AG KGaA's Enterprise Value is €3,146.8 Mil.
Schott Pharma AG KGaA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €58.6 Mil. Therefore, Schott Pharma AG KGaA's EV-to-FCF for today is 53.69.
The historical rank and industry rank for Schott Pharma AG KGaA's EV-to-FCF or its related term are showing as below:
CHIX:1SXPd'
s EV-to-FCF Range Over the Past 10 Years
Min: -1706.69 Med: 76.68 Max: 833.69
Current: 52.92
During the past 6 years, the highest EV-to-FCF of Schott Pharma AG KGaA was 833.69. The lowest was -1706.69. And the median was 76.68.
CHIX:1SXPd's EV-to-FCF is ranked worse than 78.74% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.695
vs CHIX:1SXPd: 52.92
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Schott Pharma AG KGaA (CHIX:1SXPd) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Schott Pharma AG KGaA's PE Ratio (TTM) for today is calculated as:
Schott Pharma AG KGaA's share price for today is €14.47.
Schott Pharma AG KGaA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.950.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:1SXPD vs ISRG, BDX, MDLN: EV-to-FCF Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's EV-to-FCF falls into.
Schott Pharma AG KGaA's current Enterprise Value is €3,146.8 Mil.
Schott Pharma AG KGaA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €58.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (CHIX:1SXPD) has a EV-to-FCF of 53.69 as of Jul. 15, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Schott Pharma AG KGaA and its competitors. This is 30% below median its historical median of 76.68. According to the industry distribution chart, Schott Pharma AG KGaA ranks #326 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 78.7%.
Is Schott Pharma AG KGaA's EV-to-FCF too high?
Schott Pharma AG KGaA's current EV-to-FCF of 53.69 is 30% below median its 10-year median of 76.68. The Medical Devices & Instruments industry median EV-to-FCF is 23.70. Schott Pharma AG KGaA's value of 53.69 is 126.6% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #326 out of 414 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's EV-to-FCF compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #326 out of 414 companies for EV-to-FCF. This places Schott Pharma AG KGaA in the lower half of its industry. The industry median EV-to-FCF is 23.70. Schott Pharma AG KGaA's value of 53.69 is 126.6% above this benchmark. While the company's 10-year median is 76.68 vs. the industry median of 23.70, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.70, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current EV-to-FCF of 53.69 is 126.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current EV-to-FCF is 53.69, which is 30% below median its own 10-year median of 76.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (CHIX:1SXPD) has a current EV-to-FCF of 53.69. The stock's GF Value™ is €20.10, compared to a current price of €14.47 — trading 28% below its estimated fair value. The current EV-to-FCF is 53.69, which is 30% below median its 10-year median of 76.68 and 126.6% above the Medical Devices & Instruments industry median of 23.70. Schott Pharma AG KGaA's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Schott Pharma AG KGaA (CHIX:1SXPD), the current EV-to-FCF is 53.69 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (CHIX:1SXPD) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €14.47 is trading 28% below its estimated GF Value™ of €20.10.
Key valuation signals for CHIX:1SXPD:
EV-to-FCF: 53.69 (30% below median its 10-year median of 76.68)
GF Value™: €20.10 vs. price of €14.47 (28% below fair value)
Industry Position: 126.6% above the Medical Devices & Instruments median (#326 of 414)
No single metric tells the full story. See the CHIX:1SXPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
71GF Score
Get the complete analysis for CHIX:1SXPD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:1SXPD has been successfully added to your 
